Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BIVV

Bioverativ (BIVV) Stock Price, News & Analysis

Bioverativ logo

About Bioverativ Stock (NASDAQ:BIVV)

Advanced Chart

Key Stats

Today's Range
$104.98
$104.98
50-Day Range
$104.98
$104.98
52-Week Range
$48.14
$105.01
Volume
N/A
Average Volume
3.03 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive BIVV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioverativ and its competitors with MarketBeat's FREE daily newsletter.

BIVV Stock News Headlines

Biogen Inc 0R1B Stock Quote
EDU Crosses Above Average Analyst Target
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t. With 40+ years of market modeling, he says Musk’s move wasn’t about efficiency — it was a signal. And what’s coming next could divide the market into winners and losers faster than anyone expects. Watch this urgent video briefing now.
See More Headlines

BIVV Stock Analysis - Frequently Asked Questions

Bioverativ Inc. (NASDAQ:BIVV) issued its quarterly earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.25. The company's quarterly revenue was up 27.2% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioverativ investors own include Rexford Industrial Realty (REXR), Biogen (BIIB), Spark Therapeutics (ONCE), Bristol-Myers Squibb (BMY), Phillips 66 (PSX), Gilead Sciences (GILD) and Marinus Pharmaceuticals (MRNS).

Company Calendar

Last Earnings
10/26/2017
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:BIVV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:BIVV) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners